Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy

Essa M. Essa, Michael R. Zile, Robert E. Stroud, Allison Rice, Richard J Gumina, Carl V. Leier, Francis G. Spinale

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Transient changes in the composition of the myocardial extracellular matrix may contribute to the ventricular systolic dysfunction in stress-induced cardiomyopathy (SIC). We examined the changes in plasma matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) that occur early after the clinical presentation of SIC. Methods and Results: Ten patients with SIC were enrolled. Plasma concentrations of the 6 major MMPs (1, 2, 3, 7, 8, and 9) and all 4 TIMPs (1, 2, 3, and 4) were analyzed and compared with data from 15 control subjects. Within 24 hours of the clinical presentation, SIC patients had lower MMP-1 levels (0.41 ± 0.13 vs 0.70 ± 0.13 pg/mL; P =.048) and MMP-8 levels (1.61 ± 0.34 vs 4.84 ± 1.38 pg/mL; P =.001) and higher TIMP-4 levels (3.06 ± 0.40 vs 2.16 ± 0.18 pg/mL; P =.05) compared with control. Seven of 9 SIC patients had elevated LV end-diastolic pressures, and all had normal LV end-diastolic dimensions and volumes. Conclusions: Patients afflicted with SIC had MMP and TIMP profiles similar to those described in hypertensive heart disease and diastolic heart failure and different from the profiles following myocardial infarction. Our findings uncovered a unique biomolecular profile in SIC during the first 24 hours of presentation.

Original languageEnglish (US)
Pages (from-to)487-492
Number of pages6
JournalJournal of Cardiac Failure
Volume18
Issue number6
DOIs
StatePublished - Jun 1 2012

Fingerprint

Takotsubo Cardiomyopathy
Tissue Inhibitor of Metalloproteinases
Matrix Metalloproteinase Inhibitors
Matrix Metalloproteinases
Matrix Metalloproteinase 1
Diastolic Heart Failure
Matrix Metalloproteinase 8
Ventricular Dysfunction
Tissue Inhibitor of Metalloproteinase-2
Tissue Inhibitor of Metalloproteinase-1
Matrix Metalloproteinase 2
Extracellular Matrix
Heart Diseases
Myocardial Infarction
Blood Pressure

Keywords

  • Metalloproteinases
  • cardiomyopathy
  • stress
  • stress-induced cardiomyopathy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. / Essa, Essa M.; Zile, Michael R.; Stroud, Robert E.; Rice, Allison; Gumina, Richard J; Leier, Carl V.; Spinale, Francis G.

In: Journal of Cardiac Failure, Vol. 18, No. 6, 01.06.2012, p. 487-492.

Research output: Contribution to journalArticle

Essa, Essa M. ; Zile, Michael R. ; Stroud, Robert E. ; Rice, Allison ; Gumina, Richard J ; Leier, Carl V. ; Spinale, Francis G. / Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy. In: Journal of Cardiac Failure. 2012 ; Vol. 18, No. 6. pp. 487-492.
@article{d1ce9b9f299d401eb36da9d28cf7b1ae,
title = "Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy",
abstract = "Background: Transient changes in the composition of the myocardial extracellular matrix may contribute to the ventricular systolic dysfunction in stress-induced cardiomyopathy (SIC). We examined the changes in plasma matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) that occur early after the clinical presentation of SIC. Methods and Results: Ten patients with SIC were enrolled. Plasma concentrations of the 6 major MMPs (1, 2, 3, 7, 8, and 9) and all 4 TIMPs (1, 2, 3, and 4) were analyzed and compared with data from 15 control subjects. Within 24 hours of the clinical presentation, SIC patients had lower MMP-1 levels (0.41 ± 0.13 vs 0.70 ± 0.13 pg/mL; P =.048) and MMP-8 levels (1.61 ± 0.34 vs 4.84 ± 1.38 pg/mL; P =.001) and higher TIMP-4 levels (3.06 ± 0.40 vs 2.16 ± 0.18 pg/mL; P =.05) compared with control. Seven of 9 SIC patients had elevated LV end-diastolic pressures, and all had normal LV end-diastolic dimensions and volumes. Conclusions: Patients afflicted with SIC had MMP and TIMP profiles similar to those described in hypertensive heart disease and diastolic heart failure and different from the profiles following myocardial infarction. Our findings uncovered a unique biomolecular profile in SIC during the first 24 hours of presentation.",
keywords = "Metalloproteinases, cardiomyopathy, stress, stress-induced cardiomyopathy",
author = "Essa, {Essa M.} and Zile, {Michael R.} and Stroud, {Robert E.} and Allison Rice and Gumina, {Richard J} and Leier, {Carl V.} and Spinale, {Francis G.}",
year = "2012",
month = "6",
day = "1",
doi = "10.1016/j.cardfail.2012.04.002",
language = "English (US)",
volume = "18",
pages = "487--492",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy

AU - Essa, Essa M.

AU - Zile, Michael R.

AU - Stroud, Robert E.

AU - Rice, Allison

AU - Gumina, Richard J

AU - Leier, Carl V.

AU - Spinale, Francis G.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Background: Transient changes in the composition of the myocardial extracellular matrix may contribute to the ventricular systolic dysfunction in stress-induced cardiomyopathy (SIC). We examined the changes in plasma matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) that occur early after the clinical presentation of SIC. Methods and Results: Ten patients with SIC were enrolled. Plasma concentrations of the 6 major MMPs (1, 2, 3, 7, 8, and 9) and all 4 TIMPs (1, 2, 3, and 4) were analyzed and compared with data from 15 control subjects. Within 24 hours of the clinical presentation, SIC patients had lower MMP-1 levels (0.41 ± 0.13 vs 0.70 ± 0.13 pg/mL; P =.048) and MMP-8 levels (1.61 ± 0.34 vs 4.84 ± 1.38 pg/mL; P =.001) and higher TIMP-4 levels (3.06 ± 0.40 vs 2.16 ± 0.18 pg/mL; P =.05) compared with control. Seven of 9 SIC patients had elevated LV end-diastolic pressures, and all had normal LV end-diastolic dimensions and volumes. Conclusions: Patients afflicted with SIC had MMP and TIMP profiles similar to those described in hypertensive heart disease and diastolic heart failure and different from the profiles following myocardial infarction. Our findings uncovered a unique biomolecular profile in SIC during the first 24 hours of presentation.

AB - Background: Transient changes in the composition of the myocardial extracellular matrix may contribute to the ventricular systolic dysfunction in stress-induced cardiomyopathy (SIC). We examined the changes in plasma matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) that occur early after the clinical presentation of SIC. Methods and Results: Ten patients with SIC were enrolled. Plasma concentrations of the 6 major MMPs (1, 2, 3, 7, 8, and 9) and all 4 TIMPs (1, 2, 3, and 4) were analyzed and compared with data from 15 control subjects. Within 24 hours of the clinical presentation, SIC patients had lower MMP-1 levels (0.41 ± 0.13 vs 0.70 ± 0.13 pg/mL; P =.048) and MMP-8 levels (1.61 ± 0.34 vs 4.84 ± 1.38 pg/mL; P =.001) and higher TIMP-4 levels (3.06 ± 0.40 vs 2.16 ± 0.18 pg/mL; P =.05) compared with control. Seven of 9 SIC patients had elevated LV end-diastolic pressures, and all had normal LV end-diastolic dimensions and volumes. Conclusions: Patients afflicted with SIC had MMP and TIMP profiles similar to those described in hypertensive heart disease and diastolic heart failure and different from the profiles following myocardial infarction. Our findings uncovered a unique biomolecular profile in SIC during the first 24 hours of presentation.

KW - Metalloproteinases

KW - cardiomyopathy

KW - stress

KW - stress-induced cardiomyopathy

UR - http://www.scopus.com/inward/record.url?scp=84861634617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861634617&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2012.04.002

DO - 10.1016/j.cardfail.2012.04.002

M3 - Article

VL - 18

SP - 487

EP - 492

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 6

ER -